By 2030, China aims to be the leading healthcare market in the world and our aspiration is for Roche to become a leading healthcare company in China - delivering improved care to the world’s largest population.
For more than 90 years Roche has had a strong presence in China. We were the first multinational healthcare company to set up a fully owned R&D center in Shanghai with the aim to discover and develop more breakthrough medicines in China for Chinese patients - and patients all over the world. We believe China's scale, commitment and emerging innovation in healthcare presents a unique opportunity to contribute for Roche and our partners.
Roche Accelerator is the first in-house accelerator globally, representing Roche’s long-term commitment to Shanghai and China. Roche Accelerator strengthens the collaboration with local partners and plays a key part in the local innovation ecosystem.
Embedded in the Roche R&D organization, the Accelerator catalyses and empowers entrepreneurs to bridge the gap between concept and proof-of-concept through Roche’s dedicated team, full-spectrum research and development (R&D) and commercial capabilities in China. We could provide seed funding, intensive coaching and guidance, and best-in-class in-house scientific avenues to discuss topics as detailed as assays, or with strategic breadth, like defining key milestones to de-risk the science. We do this together with our partners, where they can add value.
Located in the heart of Zhangjiang of Pudong, Shanghai, the building of Roche Accelerator is inaugurated in 2023. The 5,000-square-meter building is the home to state-of-the-art laboratories, offices, and collaboration spaces for entrepreneurs focusing on pharma, diagnostics, and personalized healthcare (PHC) including artificial intelligence (AI) and digital solutions.
Infrastructure: Roche Accelerator is located in Shanghai. The 5,000-square-meter building is the home to state-of-the-art laboratories, offices, and collaboration spaces for entrepreneurs
Support: Scientific and strategic mentorship from Roche business leaders, senior scientists, distinguished experts, investors as well as a community platform for portfolio companies to connect and collaborate
Funding: Potential Roche seed funding available in the forms of equity investment, research funding or subsidies; priority access to our venture capital partners
Operations: Procurement and Logistics, Environment, Health and Safety, IT and network, and preferential benefits from Roche recommended vendors and potential tax incentives and government subsidies
Flexibility: A flexible program that can be tailored to the individual needs of each entrepreneur, depending on where you are in your journey
We focus on the following areas: pharma, diagnostics and personalised healthcare (PHC) including AI and digital solutions - a strategy that aims to fit the right treatment to each person in the best way possible. Being agnostic to the company stage, we are interested in discovery, translational and early development projects with a special focus on:
We invite you to join us and start something amazing!
We focus on the following areas: pharma, diagnostics and personalised healthcare (PHC) including AI and digital solutions - a strategy that aims to fit the right treatment to each person in the best way possible. Being agnostic to the company stage, we are interested in discovery, translational and early development projects with a special focus on:
Have a look at our Roche Accelerator members. We hope that together we can build a better future with medical advances that make a real difference to people’s health.
Founded in March 2021,
At
Keen focuses on challenging targets / pathways to provide innovative cancer therapies, by specialising in the area of cancer metabolism including ferroptosis and macropinocytosis.
Portal's mission is to conquer critical cell therapy challenges. We're developing solutions for effective biomolecule delivery and cell function enhancements. Our vision is to democratize cell therapy access globally, ensuring cost-effective technology that benefits patients worldwide.
Founded in 2021,
Syneron Tech is Innovative Peptide Therapeutics Company Empowered by Unique Platforms and the Next Generation AI Capabilities.
Synphatec pioneers cutting-edge brain disease drug development based on biological mechanistic innovations by the founders.
4B Technologies
We invite you to submit non-confidential information through
We accept applications on a rolling basis; short-listed candidates will be invited to present face-to-face to the Roche team.
Even if you believe your project is not yet mature and are hesitant to apply, we recommend that you get in contact with us. We may see the potential opportunity differently and can help advance your project. At the very least, we can help you prepare for the future.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.